TITLE

Tumor Resistance Explained by Hormesis

AUTHOR(S)
Calabrese, Edward J.; Nascarella, Marc A.
PUB. DATE
January 2010
SOURCE
Dose-Response;2010, Vol. 8 Issue 1, p80
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Enhanced drug (GDC 0449) resistance in a mouse model for human medulloblastoma is shown in the present paper to act via an hormetic response. This has significant implications, imposing constraints on the quantitative features of the dose response of the chemotherapeutic agent, affecting optimal study design, mechanism assessment strategy, potential for tumor rebound, patient relapse and disease outcome.
ACCESSION #
59192568

 

Related Articles

  • Quantification of Hormesis in Anticancer-Agent Dose-Responses. Nascarella, Marc A.; Stanek III, Edward J.; Hoffmann, George R.; Calabrese, Edward J. // Dose-Response;2009, Vol. 7 Issue 2, p160 

    Quantitative features of dose responses were analyzed for 2,189 candidate anticancer agents in 13 strains of yeast (Saccharomyces cerevisiae). The agents represent a diverse class of chemical compounds including mustards, other alkylating agents, and antimetabolites, inter alia. Previous...

  • The marginalization of hormesis. Calabrese, E.J.; Baldwin, L.A. // Human & Experimental Toxicology;Jan2000, Vol. 19 Issue 1, p32 

    Despite the substantial development and publication of highly reproducible toxicological data, the concept of hormetic dose-response relationships was never integrated into the mainstream of toxicological thought. Review of the historical foundations of the interpretation of the bioassay and...

  • Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine. Jing Jin; Feng-Peng Wang; Huailing Wei; Gengtao Liu // Cancer Chemotherapy & Pharmacology;Feb2005, Vol. 55 Issue 2, p179 

    Purpose: The present study aimed to evaluate the MDR reversal activity of bromotetrandrine (BrTet), a bromized derivative of tetrandrine (Tet), in vitro and in vivo. Methods: Drug sensitivity was determined using the MTT assay. The in vivo effect of Tet was investigated using nude mice grafted...

  • Lack of in vivo cross-resistance with 4′-thio-ara-C against drug-resistant murine P388 and L1210 leukemias. Waud, William; Gilbert, Karen; Secrist, John // Cancer Chemotherapy & Pharmacology;Aug2011, Vol. 68 Issue 2, p399 

    Purpose: 4′-Thio-β-D-arabinofuranosylcytosine (4′-thio-ara-C), which has shown a broad spectrum of antitumor activity against human tumor systems in mice and is undergoing clinical trials, was evaluated for cross-resistance to seven clinical agents in order to identify potentially...

  • Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer. Sreekanth, C N; Bava, S V; Sreekumar, E; Anto, R J // Oncogene;7/14/2011, Vol. 30 Issue 28, p3139 

    The microtubule-targeting antineoplastic agent, paclitaxel, is highly efficacious against a wide spectrum of human cancers. However, dose-limiting toxicity and development of drug resistance limit its clinical application. Development of novel strategies that overcome chemoresistance and...

  • Combination of Ononis hirta and Bifi dobacterium longum decreases syngeneic mouse mammary tumor burden and enhances immune response. Talib, Wamidh H.; Mahasneh, Adel M. // Journal of Cancer Research & Therapeutics;Jul-Sep2012, Vol. 8 Issue 3, p417 

    Background: The resistance of solid tumors to conventional therapies has prompted the need for alternative therapies. Aim: To evaluate in vitro and in vivo effect of extracts from Ononis hirta against resistant mouse mammary gland cell line (66 cl-4-GFP) and to use a combination of Ononis hirta...

  • HORMESIS: IMPLICATIONS FOR CANCER RISK ASSESSMENT. Borak, Jonathan; Sirianni, Greg // Dose-Response;2005, Vol. 3 Issue 3, p443 

    Current guidelines for cancer risk assessment emphasize a toxicant's "mode of action", rather than its empirically derived dose-response relationship, for determining whether linear low-dose extrapolation is appropriate. Thus, for reasons of policy, demonstration of hormesis is generally...

  • Some implications for quantitative risk assessment if hormesis exists. Sielken Jr, R.L.; Stevenson, D.E. // Human & Experimental Toxicology;1998, Vol. 17 Issue 5, p259 

    The existence of hormesis should impact quantitative risk assessment in at least seven fundamental ways. (1) The dose-reponse models for bioassay and epidemiological data should have greater flexibility to fit the observed shape of the dose-response data and no longer be forced to always be...

  • Implications of hormesis on the bioassay and hazard assessment of chemical carcinogens. Teeguarden, J.G.; Dragan, Y.P.; Pitot, H.C. // Human & Experimental Toxicology;1998, Vol. 17 Issue 5, p254 

    Hormesis has been defined as a dose-response relationship which depicts improvement in some endpoint (increased metabolic rates, reduction in tumor incidence, etc.) at low doses of a toxic compound followed by a decline in the endpoint at higher doses. The existence of hormetic responses to...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics